Meta-analysis of efruxifermin shows significant liver benefits in NASH/MASH patients with short follow-up.
New Drug Clears Fat and Scar From Liver
This systematic review and meta-analysis evaluated efruxifermin versus placebo in 419 patients with NASH/MASH. The authors synthesized data …
A new drug helps clear fat and repair scar tissue in the liver, offering a direct fix for serious damage beyond just weight loss.
Efruxifermin shows superior fibrosis regression in compensated MASH cirrhosis compared to placebo in a network meta-analysis.
New drug ranking shows one treatment stands out for advanced fatty liver scarring
This network meta-analysis evaluated histological efficacy in patients with biopsy-proven compensated metabolic dysfunction-associated steat…
Efruxifermin is the only drug proven to shrink advanced liver scarring without worsening the disease, ranking first among new treatments for…